<?xml version="1.0" encoding="UTF-8"?>
<urlset
  xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
  xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.weightlossrankings.org/research/bariatric-surgery-vs-glp1-decision-guide</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Bariatric Surgery vs GLP-1 vs Combination: A Decision Guide With 13 Verified Trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/mounjaro-zepbound-fda-prescribing-information-explained</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Mounjaro vs Zepbound: FDA Prescribing Information Explained Side-by-Side</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/mounjaro-zepbound-informacion-prescripcion-fda</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-09T00:00:00.000Z</news:publication_date>
      <news:title>Mounjaro vs Zepbound: La información de prescripción de la FDA explicada lado a lado</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/glp1-bone-density-fracture-risk-evidence</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1 Medications and Bone Density / Fracture Risk: What the Meta-Analyses, Cohort Data, and Older-Adult Sub-Analyses Actually Show</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/glp1-densidad-osea-riesgo-fractura-evidencia</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1 y densidad ósea / riesgo de fractura: lo que muestran los metanálisis, los datos de cohortes y los subanálisis en adultos mayores</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/ozempic-face-glp1-facial-volume-loss-evidence</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>Ozempic Face: GLP-1-Related Facial Volume Loss — What the Imaging Data and the Aesthetic-Surgery Literature Actually Show</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.weightlossrankings.org/research/ozempic-face-glp1-perdida-volumen-facial-evidencia</loc>
    <news:news>
      <news:publication>
        <news:name>Weight Loss Rankings</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-05-08T00:00:00.000Z</news:publication_date>
      <news:title>&quot;Ozempic face&quot;: pérdida de volumen facial con GLP-1 — lo que muestran los datos de imágenes y la literatura quirúrgica estética</news:title>
    </news:news>
  </url>
</urlset>